𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II

✍ Scribed by G. Schulze-Frenking; Simon A. Jones; J. Roberts; M. Beck; J. E. Wraith

Publisher
Springer
Year
2010
Tongue
English
Weight
134 KB
Volume
34
Category
Article
ISSN
0141-8955

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Mutational analysis of mucopolysaccharid
Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy
✍ L. Karageorgos; P. Harmatz; J. Simon; A. Pollard; P. R. Clements; D. A. Brooks; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 121 KB πŸ‘ 1 views

## Communicated by Andreas Gal Mucopolysaccharidosis type VI (MPS VI), or Maroteaux-Lamy syndrome, is a lysosomal storage disorder caused by a deficiency of N-acetylgalactosamine-4-sulfatase (ARSB). Seven MPS VI patients were chosen for the initial clinical trial of enzyme replacement therapy. Dir

Identification and molecular characteriz
Identification and molecular characterization of Ξ±-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy
✍ G. Yogalingam; X.-H. Guo; V.J. Muller; D.A. Brooks; P.R. Clements; E.D. Kakkis; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 259 KB πŸ‘ 1 views

Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase (IDUA). Mutations in the gene are responsible for the enzyme deficiency, which leads to the intralysosomal storage of the partially degraded glycosaminoglycans derm